Abstract:Objectives: During the advancement of atherosclerosis, plaque cellularity is governed by the influx of monocyte-derived macrophages and their turnover via apoptotic and nonapoptotic forms of cell death. Previous reports have demonstrated that programmed necrosis, or necroptosis, of plaque macrophages contribute to necrotic core formation. Knockdown or inhibition of the necrosome components RIPK1 (receptor-interacting protein kinase 1) and RIPK3 (receptor-interacting protein kinase 3) slow atherogenesis, and activation of the terminal step of necroptosis, MLKL (mixed lineage kinase domain-like protein), has been demonstrated in advanced human atherosclerotic plaques. However, whether MLKL directly contributes to lesion development and necrotic core formation has not been investigated. Approaches and Results: MLKL expression was knocked down in atherogenic Apoe-knockout mice via the administration of antisense oligonucleotides. During atherogenesis, Mlkl knockdown decreased both programmed cell death and the necrotic core in the plaque. However, total lesion area remained unchanged. Furthermore, treatment with the MLKL antisense oligonucleotide unexpectedly reduced circulating cholesterol levels compared with control antisense oligonucleotide but increased the accumulation of lipids within the plaque and in vitro in macrophage foam cells. MLKL colocalized with the late endosome and multivesicular bodies in peritoneal macrophages incubated with atherogenic lipoproteins. Transfection with MLKL antisense oligonucleotide increased lipid localization with the multivesicular bodies, suggesting that upon Mlkl knockdown, lipid trafficking becomes defective leading to enhanced lipid accumulation in macrophages. Conclusions: These studies confirm the requirement for MLKL as the executioner of necroptosis, and as such a significant contributor to the necrotic core during atherogenesis. We also identified a previously unknown role for MLKL in regulating endosomal trafficking to facilitate lipid handling in macrophages during atherogenesis.

Acylation of MLKL Impacts Its Function in Necroptosis

The MLKL Channel in Necroptosis is an Octamer Formed by Tetramers in a Dyadic Process.

Oligomerization-driven MLKL ubiquitylation antagonizes necroptosis

Biological events and molecular signaling following MLKL activation during necroptosis

Translocation of mixed lineage kinase domain-like protein to plasma membrane leads to necrotic cell death

Uncovering human mixed lineage kinase domain-like activation in necroptosis

Phosphorylation-dependent pseudokinase domain dimerization drives full-length MLKL oligomerization

Characterization of RIPK3-mediated phosphorylation of the activation loop of MLKL during necroptosis

The MLKL kinase-like domain dimerization is an indispensable step of mammalian MLKL activation in necroptosis signaling

Loss of MLKL (Mixed Lineage Kinase Domain-Like Protein) Decreases Necrotic Core but Increases Macrophage Lipid Accumulation in Atherosclerosis

Necrosome core machinery: MLKL

Death at a funeral: Activation of the dead enzyme, MLKL, to kill cells by necroptosis

A necroptotic-independent function of MLKL in regulating endothelial cell adhesion molecule expression

Locking mixed-lineage kinase domain-like protein in its auto-inhibited state prevents necroptosis

The Many Faces of MLKL, the Executor of Necroptosis

Mixed Lineage Kinase Domain-Like Protein MLKL Causes Necrotic Membrane Disruption Upon Phosphorylation by RIP3.

LUBAC-mediated M1 Ub regulates necroptosis by segregating the cellular distribution of active MLKL

Positive Charges in the Brace Region Facilitate the Membrane Disruption of MLKL-NTR in Necroptosis

Direct Activation of Human MLKL by a Select Repertoire of Inositol Phosphate Metabolites

Characterization of MLKL-mediated Plasma Membrane Rupture in Necroptosis

Necroptosis executioner MLKL plays pivotal roles in agonist-induced platelet prothrombotic responses and lytic cell death in a temporal order